Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001104659-17-009121)

Filing Details

Accession Number:
0001104659-17-009121
Form Type:
13G Filing
Publication Date:
2017-02-14 13:12:40
Filed By:
Versant Side Fund Iv, L.p.
Company:
Audentes Therapeutics Inc. (NASDAQ:BOLD)
Filing Date:
2017-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Versant Side Fund IV 11,308 0 11,308 0 11,308 0.1%
Versant Venture Capital IV 1,795,524 0 1,795,524 0 1,795,524 8.3%
Versant Ventures IV 0 1,806,832 0 1,806,832 1,806,832 8.4%
Filing

 

 

UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

 

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)
(Amendment No.    )*

 

Audentes Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

05070R104

(CUSIP Number)

December 31, 2016

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o

Rule 13d-1(b)

o

Rule 13d-1(c)

x

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP No. 05070R104

13 G

 

 

 

1

Names of Reporting Persons.
Versant Side Fund IV, L.P.

 

 

2

Check the Appropriate Box if a Member of a Group*

 

 

(a)

o

 

 

(b)

x (1)

 

 

3

SEC Use Only

 

 

4

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5

Sole Voting Power
11,308 (2)

 

6

Shared Voting Power
0 shares

 

7

Sole Dispositive Power
11,308 (2)

 

8

Shared Dispositive Power
0 shares

 

 

9

Aggregate Amount Beneficially Owned by Each Reporting Person
11,308 (2)

 

 

10

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares*  o

 

 

11

Percent of Class Represented by Amount in Row 9
0.1% (3)

 

 

12

Type of Reporting Person*
PN

 

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV) and Versant Ventures IV, LLC, a Delaware limited liability company (VV IV) (collectively, the Reporting Persons).  The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2016.

(3) This percentage is calculated based upon 21,725,163 shares of Common Stock outstanding as of November 8, 2016 as set forth in the Issuers most recent 10-Q filed with the Securities and Exchange Commissions on November 10, 2016.

 

2

 

CUSIP No. 05070R104

13 G

 

 

 

1

Names of Reporting Persons.
Versant Venture Capital IV, L.P.

 

 

2

Check the Appropriate Box if a Member of a Group*

 

 

(a)

o

 

 

(b)

x (1)

 

 

3

SEC Use Only

 

 

4

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5

Sole Voting Power
1,795,524 (2)

 

6

Shared Voting Power
0 shares

 

7

Sole Dispositive Power
1,795,524 (2)

 

8

Shared Dispositive Power
0 shares

 

 

9

Aggregate Amount Beneficially Owned by Each Reporting Person
1,795,524 (2)

 

 

10

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares*  o

 

 

11

Percent of Class Represented by Amount in Row 9
8.3% (3)

 

 

12

Type of Reporting Person*
PN

 

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV) and Versant Ventures IV, LLC, a Delaware limited liability company (VV IV) (collectively, the Reporting Persons).  The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2016.

(3) This percentage is calculated based upon 21,725,163 shares of Common Stock outstanding as of November 8, 2016 as set forth in the Issuers most recent 10-Q filed with the Securities and Exchange Commissions on November 10, 2016.

 

3

 

CUSIP No. 05070R104

13 G

 

 

 

1

Names of Reporting Persons
Versant Ventures IV, LLC

 

 

2

Check the Appropriate Box if a Member of a Group*

 

 

(a)

o

 

 

(b)

x (1)

 

 

3

SEC Use Only

 

 

4

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5

Sole Voting Power
0 shares

 

6

Shared Voting Power
1,806,832 (2)

 

7

Sole Dispositive Power
0 shares

 

8

Shared Dispositive Power
1,806,832 (2)

 

 

9

Aggregate Amount Beneficially Owned by Each Reporting Person
1,806,832 (2)

 

 

10

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares*  o

 

 

11

Percent of Class Represented by Amount in Row 9
8.4% (3)

 

 

12

Type of Reporting Person*
OO

 

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV) and Versant Ventures IV, LLC, a Delaware limited liability company (VV IV) (collectively, the Reporting Persons).  The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2)  Includes: (i) 11,308 shares held by VSF IV; and (ii) 1,795,524 shares held by VVC IV.  VV IV serves as the sole general partner of VSF IV and VVC IV and owns no securities of the Issuer directly.  The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2016.

(3)  This percentage is calculated based upon 21,725,163  shares of Common Stock outstanding as of November 8, 2016 as set forth in the Issuers most recent 10-Q filed with the Securities and Exchange Commissions on November 10, 2016.

 

4

 

Introductory Note: This Statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value $0.0001 per share (Common Stock), of Audentes Therapeutics, Inc. (the Issuer).

 

Item 1

 

(a)

Name of Issuer:
Audentes Therapeutics, Inc.

 

 

Address of Issuers Principal Executive Offices:
600 California Drive, 17th Floor

San Francisco, CA  94104

 

Item 2

 

(a)

Name of Person(s) Filing:
Versant Side Fund IV, L.P.  (VSF IV)

Versant Venture Capital IV, L.P.  (VVC IV)

Versant Ventures IV, LLC (VV IV)

 

(b)

Address of Principal Business Office:
c/o Versant Venture Management, LLC

One Sansome Street, Suite 3630

San Francisco, CA  94104

 

(b)

Citizenship:
Entities:        VSF IV                                     -                                            Delaware

       VVC IV                               -                                            Delaware

       VV IV                                        -                                            Delaware

 

(d)

Title of Class of Securities:
Common Stock

 

(e)

CUSIP Number:
05070R104

 

Item 3

Not applicable.

 

Item 4

Ownership.

The following information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2016:

 

Reporting Persons

 

Shares
Held
Directly

 

Sole
Voting
Power

 

Shared
Voting
Power

 

Sole
Dispositive
Power

 

Shared
Dispositive
Power

 

Beneficial
Ownership

 

Percentage
of Class
(2)

 

VSF IV

 

11,308

 

11,308

 

0

 

11,308

 

0

 

11,308

 

0.1

%

VVC IV

 

1,795,524

 

1,795,524

 

0

 

1,795,524

 

0

 

1,795,524

 

8.3

%

VV IV(1)

 

0

 

0

 

1,806,832

 

0

 

1,806,832

 

1,806,832

 

8.4

%

 

(1) VV IV serves as the sole general partner of VSF IV and VVC IV and owns no securities of the Issuer directly.

(2) This percentage is calculated based upon 21,725,163 shares of Common Stock outstanding as of November 8, 2016.

 

5

 

Item 5

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof, the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:   o

 

Item 6

Ownership of More than Five Percent on Behalf of Another Person.

 

See Items 2(a) and 4.

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8

Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9

Notice of Dissolution of Group.

 

Not applicable.

 

 

Item 10

Certification.

 

Not applicable.

 

6

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 13, 2017

 

Versant Side Fund IV, L.P.

 

 

 

 

By:

Versant Ventures IV, LLC

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Authorized Representative

 

 

 

 

Versant Venture Capital IV, L.P.

 

 

 

 

By:

Versant Ventures IV, LLC

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Authorized Representative

 

 

 

 

Versant Ventures IV, LLC

 

 

 

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Managing Member

 

 

7

 

Exhibit(s):

 

A - Joint Filing Statement

 

8

 

 

 

 

 

 

 

EXHIBIT A

 

JOINT FILING STATEMENT

 

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Audentes Therapeutics, Inc. is filed on behalf of each of us.

 

Dated: February 13, 2017

 

Versant Side Fund IV, L.P.

 

 

 

 

By:

Versant Ventures IV, LLC

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Authorized Representative

 

 

 

 

Versant Venture Capital IV, L.P.

 

 

 

 

By:

Versant Ventures IV, LLC

 

Its:

General Partner

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Authorized Representative

 

 

 

 

Versant Ventures IV, LLC

 

 

 

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Managing Member

 

 

9